Table 2.

Lipid profile (mmol l⁻¹) in subjects treated with placebo or policosanol (mean ± s.e.mean results).

Group	Baseline	8 weeks	%
Total cholesterol
Placebo	4.40 ± 0.66	4.57 ± 0.55	+ 4.4
Policosanol-5	4.60 ± 0.72	4.10 ± 0.63****+ +	−10.5+ + + +
Policosanol-10	4.64 ± 0.58	4.06 ± 0.64 ****+ +	−12.4+ + + +
LDL-C
Placebo	2.99 ± 0.63	3.12 ± 0.51	+ 7.3
Policosanol-5	3.19 ± 0.67	2.65 ± 0.66 ****+	−16.7+ + + +
Policosanol-10	3.28 ± 0.63	2.64 ± 0.67 ****+	−20.2+ + + +
HDL-C
Placebo	0.96 ± 0.25	0.94 ± 0.21	−1.8
Policosanol-5	0.98 ± 0.22	1.07 ± 0.28 **+	+ 9.0+
Policosanol-10	0.96 ± 0.22	1.08 ± 0.21 ***+	+ 15.2+ +
Triglycerides
Placebo	1.21 ± 0.42	1.37 ± 0.66	+ 17.6
Policosanol-5	1.14 ± 0.49	1.03 ± 0.49+	−9.7b
Policosanol-10	1.06 ± 0.45	0.90 ± 0.39 **+a	−9.4b

% percent changes (−) decrease; (+) increase.

^**P < 0.01

^***P < 0.001

^****P < 0.0001. Comparison with baseline (Wilcoxon Test for paired samples).

^bP = 0.05

⁺P < 0.05

^{+ +}P < 0.01

^{+ + + +}P < 0.0001. Compared with placebo (Mann Whitney U-test)

^asignificantly different for the level of significance P < 0.016 (Bonferroni correction).